{"id":251095,"date":"2022-03-01T00:00:00","date_gmt":"2022-03-01T00:00:00","guid":{"rendered":"https:\/\/clarivate.com\/products\/research-reports\/report\/epidop0025-biopharma-diabetic-retinopathy-epidemiology-europe\/"},"modified":"2026-03-31T10:40:32","modified_gmt":"2026-03-31T10:40:32","slug":"epidop0025-biopharma-diabetic-retinopathy-epidemiology-europe","status":"publish","type":"report","link":"https:\/\/clarivate.com\/life-sciences-healthcare\/report\/epidop0025-biopharma-diabetic-retinopathy-epidemiology-europe\/","title":{"rendered":"Diabetic Retinopathy &#8211; Epidemiology &#8211; Europe"},"content":{"rendered":"<p>Clarivate Epidemiology\u2019s coverage of diabetic retinopathy (<abbr data-abbreviation-entity=\"6398\" title=\"diabetic retinopathy\">DR<\/abbr>) comprises epidemiological estimates of key patient populations in 45 countries worldwide. We report the prevalence of <abbr data-abbreviation-entity=\"6398\" title=\"diabetic retinopathy\">DR<\/abbr> for each country, as well as annualized case counts projected to the national population.<\/p>\n<p>Most patient populations are forecast over a period of 20 years for the major mature pharmaceutical markets and 10 years for the remaining countries covered in this report.<\/p>\n<p>Clarivate Epidemiology\u2019s <abbr data-abbreviation-entity=\"6398\" title=\"diabetic retinopathy\">DR<\/abbr> forecast will answer the following questions:<\/p>\n<ul class=\"round-bullets\">\n<li>Of all people with <abbr title=\"diabetic retinopathy\">DR<\/abbr>, how many in each of the major mature pharmaceutical markets are diagnosed?<\/li>\n<li>Of all people with <abbr title=\"diabetic retinopathy\">DR<\/abbr>, how many in each of the major mature pharmaceutical markets are drug-treated?<\/li>\n<li>How will demographic trends, such as population aging and improving life expectancy, affect the epidemiology of <abbr data-abbreviation-entity=\"6398\" title=\"diabetic retinopathy\">DR<\/abbr> over the forecast period?<\/li>\n<\/ul>\n<p>All forecast data are available on the Clarivate Insights Platform in tabular format, with options to download to Excel. All populations are accompanied by a comprehensive description of the methods and data sources used, with hyperlinks to external sources. A summary evidence table generated as part of our systematic review of the epidemiological literature is provided for full transparency into research and methods.<\/p>\n<p>Clarivate Epidemiology provides at least 10 years of forecast data for the following <abbr data-abbreviation-entity=\"6398\" title=\"diabetic retinopathy\">DR<\/abbr> patient populations:<\/p>\n<ul class=\"round-bullets\">\n<li>Total prevalent cases of <abbr title=\"diabetic retinopathy\">DR<\/abbr>.<\/li>\n<li>Total prevalent cases of proliferative <abbr title=\"diabetic retinopathy\">DR<\/abbr>.<\/li>\n<li>Total prevalent cases of nonproliferative <abbr title=\"diabetic retinopathy\">DR<\/abbr>.<\/li>\n<li>Total prevalent cases of nonproliferative <abbr title=\"diabetic retinopathy\">DR<\/abbr> by severity subtype.<\/li>\n<li><abbr title=\"diagnosed\">Dx<\/abbr> prevalent cases of severe nonproliferative <abbr title=\"diabetic retinopathy\">DR<\/abbr>.<\/li>\n<li><abbr title=\"diagnosed\">Dx<\/abbr> prevalent cases of proliferative <abbr title=\"diabetic retinopathy\">DR<\/abbr>.<\/li>\n<li>Drug-treated prevalent cases of severe nonproliferative <abbr title=\"diabetic retinopathy\">DR<\/abbr>.<\/li>\n<li>Drug-treated prevalent cases of proliferative <abbr title=\"diabetic retinopathy\">DR<\/abbr>.<\/li>\n<\/ul>\n<p>Note: Coverage may vary by country and region.<\/p>\n","protected":false},"template":"","class_list":["post-251095","report","type-report","status-publish","hentry","report-gateway-biopharma","biopharma-therapy-areas-diabetic-retinopathy","biopharma-therapy-areas-ophthalmology","biopharma-product-epidemiology","biopharma-geography-europe","biopharma-date-960"],"acf":[],"publishpress_future_workflow_manual_trigger":{"enabledWorkflows":[]},"_links":{"self":[{"href":"https:\/\/clarivate.com\/life-sciences-healthcare\/wp-json\/wp\/v2\/report\/251095","targetHints":{"allow":["GET"]}}],"collection":[{"href":"https:\/\/clarivate.com\/life-sciences-healthcare\/wp-json\/wp\/v2\/report"}],"about":[{"href":"https:\/\/clarivate.com\/life-sciences-healthcare\/wp-json\/wp\/v2\/types\/report"}],"version-history":[{"count":1,"href":"https:\/\/clarivate.com\/life-sciences-healthcare\/wp-json\/wp\/v2\/report\/251095\/revisions"}],"predecessor-version":[{"id":283539,"href":"https:\/\/clarivate.com\/life-sciences-healthcare\/wp-json\/wp\/v2\/report\/251095\/revisions\/283539"}],"wp:attachment":[{"href":"https:\/\/clarivate.com\/life-sciences-healthcare\/wp-json\/wp\/v2\/media?parent=251095"}],"curies":[{"name":"wp","href":"https:\/\/api.w.org\/{rel}","templated":true}]}}